Thanks, Eliseo. Stay safe and well.

Best,

Tony

Hey Tony, you are the man! Best, Eliseo

Hello Eliseo and Courtney,

During the White House briefing on COVID-19 this evening, there was a discussion on the disproportionate impact of COVID-19 on African Americans, health disparities and data collection. Please see CSPAN Clips below I cued up.


I know we are not commenting but I would like to recommend that we have some talking points prepared and on hold in case we receive congressional inquiries. These topics are also receiving coverage on the networks.

Thank you,

Natasha
From: Fauci, Anthony (NIH/NIAID) [E]  
Sent: Wed, 8 Apr 2020 03:06:30 +0000  
To: Grogan, Joseph J. EOP/WHO  
Cc: Bonner, Maria K. EOP/WHO; Campana, Alexandra D. EOP/WHO; Barasch, Kimberly (NIH/NIAID) [C]; Conrad, Patricia (NIH/NIAID) [E]  
Subject: RE: [EXTERNAL] RE: Good news

Joe:

I would be happy to speak with him. However, it would have to wait until Thursday since tomorrow is impossible. I believe that we can work this out. Perhaps we can arrange for a call between me, the CEO and some knowledgeable people in my program.  
Best regards,  
Tony

From: Grogan, Joseph J. EOP/WHO  
Sent: Tuesday, April 7, 2020 10:19 PM  
To: Fauci, Anthony (NIH/NIAID) [E]  
Cc: Bonner, Maria K. EOP/WHO; Campana, Alexandra D. EOP/WHO  
Subject: Fwd: [EXTERNAL] RE: Good news

Dr., I would never abuse your personal email, but since the CEO of Lilly wants to speak with you, I thought I would share this request. Just let me know how to respond

Sent from my iPhone

Begin forwarded message:

From: Shawn O’Neil  
Date: April 7, 2020 at 10:07:37 PM EDT  
To: "Grogan, Joseph J. EOP/WHO"; "Bonner, Maria K. EOP/WHO"  
Subject: [EXTERNAL] RE: Good news

You bet.

Joe – Have an enormous request – for help or counsel.
My CEO, Dave Ricks, would like to speak with Dr. Fauci in this regard (given his role at the Institute). I know that is a tall order – but underscores the importance.

I did reach out to Dr. Fauci’s Chief but received an automated reply indicated he was behind in email – any thoughts in the regard greatly appreciated....

Best, Shawn

Shawn O’Neail
Vice President, Government Affairs
Eli Lilly and Company

CONFIDENTIALITY NOTICE: This e-mail message (including all attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Grogan, Joseph J. EOP/WHO <(b)(6)>  
Sent: Tuesday, April 7, 2020 9:31 AM  
To: Shawn O’Neail; Bonner, Maria K. EOP/WHO <(b)(6)>  
Subject: [EXTERNAL] RE: Good news

EXTERNAL EMAIL: Use caution before replying, clicking links, and opening attachments.

This is great. Thank you for sharing and everything you are doing. Joe

From: Shawn O’Neail <(b)(6)>  
Sent: Tuesday, April 7, 2020 9:26 AM  
To: Grogan, Joseph J. EOP/WHO; Bonner, Maria K. EOP/WHO <(b)(6)>  
Subject: [EXTERNAL] Good news

Hi Joe and Maria

I want to share an important update about Lilly’s efforts to address insulin affordability. In response to the crisis caused by COVID-19, Lilly is introducing the Lilly Insulin Value Program, allowing anyone with commercial insurance - and those without insurance - to fill their monthly prescription of Lilly insulin for $35. The program is effective today and
covers most Lilly insulins. Details and more information can be found in the press release here attached.

Lilly has introduced several solutions in recent years to help meet the individual financial circumstances of people living with diabetes that are still in effect during the COVID-19 crisis, including:

- The Lilly Diabetes Solution Center, through which representatives can direct people to the $35 savings card, as well as affordability options that may reduce their out-of-pocket costs further—such as free insulin for people with minimal income, or no income at all, that has been donated by Lilly to non-profit organizations.
- Three non-branded versions of our insulin options with list prices 50 percent lower than the branded versions.
- In January, the company announced plans to donate at least 200,000 KwikPens® to relief agencies over the next three years.

Hope all is well with you....

Shawn

Shawn O'Neal
Vice President, Government Affairs
Eli Lilly and Company

CONFIDENTIALITY NOTICE: This e-mail message (including all attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.
Cliff:

Let us discuss this. How do you think that I should respond?

Thanks,

Tony

Dr., I would never abuse your personal email, but since the CEO of Lilly wants to speak with you, I thought I would share this request. Just let me know how to respond.

Sent from my iPhone

Begin forwarded message:

You bet.

Joe – Have an enormous request – for help or counsel.

My CEO, Dave Ricks, would like to speak with Dr. Fauci in this regard (given his role at the Institute). I know that is a tall order – but underscores the importance.

I did reach out to Dr. Fauci’s Chief but received an automated reply indicated he was behind in email – any thoughts in the regard greatly appreciated....
Best, Shawn

Shawn O'Neail  
Vice President, Government Affairs  
Eli Lilly and Company  
(6)(office) | (6)(mobile) | www.lilly.com

CONFIDENTIALITY NOTICE: This e-mail message (including all attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Grogan, Joseph J. EOP/WHO  
Sent: Tuesday, April 7, 2020 9:31 AM  
To: Shawn O'Neail Bonner, Maria K. EOP/WHO  
Subject: [EXTERNAL] RE: Good news

EXTERNAL EMAIL: Use caution before replying, clicking links, and opening attachments.

This is great. Thank you for sharing and everything you are doing. Joe

From: Shawn O'Neail  
Sent: Tuesday, April 7, 2020 9:26 AM  
To: Grogan, Joseph J. EOP/WHO Bonner, Maria K. EOP/WHO  
Subject: [EXTERNAL] Good news

Hi Joe and Maria

I want to share an important update about Lilly's efforts to address insulin affordability. In response to the crisis caused by COVID-19, Lilly is introducing the Lilly Insulin Value Program, allowing anyone with commercial insurance - and those without insurance - to fill their monthly prescription of Lilly insulin for $35. The program is effective today and covers most Lilly insulins. Details and more information can be found in the press release here attached.

Lilly has introduced several solutions in recent years to help meet the individual financial circumstances of people living with diabetes that are still in effect during the COVID-19 crisis, including:
• The Lilly Diabetes Solution Center, through which representatives can direct people to the $35 savings card, as well as affordability options that may reduce their out-of-pocket costs further — such as free insulin for people with minimal income, or no income at all, that has been donated by Lilly to non-profit organizations.

• Three non-branded versions of our insulin options with list prices 50 percent lower than the branded versions.

• In January, the company announced plans to donate at least 200,000 KwikPens® to relief agencies over the next three years.

Hope all is well with you....

Shawn

----------------------------------
Shawn O'Neal
Vice President, Government Affairs
Eli Lilly and Company

(office) | (mobile)
(office) | >>www.lilly.com<<
(b) | (b) (b) (b)

Lilly

CONFIDENTIALITY NOTICE: This e-mail message (including all attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.
Due to the high demand on Dr. Fauci's time during the current outbreak – we must decline your request at this time. Thank you for your understanding.

Best,

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health

From: Chris Joffe <Chris@joffeemergencyservices.com>
Sent: Tuesday, April 7, 2020 6:46 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b)(6) (office)
Subject: Supporting Schools In Covid-19

Dr. Fauci -

I’m a safety/security consultant to independent and charter schools. I run a firm supporting ~1,000 of them. What, if anything, would you want them to know? I'm wondering if there's any chance in the world you'd be willing to join us and a few hundred schools for a 15 - 30-minute webinar one day next week?

Specifically, schools are looking for information/perspective as it relates to what to expect as we return to a new normal and the like. Beyond that, they've begun to ask questions such as what we can be thinking about for this short period of time between the return to school and the development of a vaccine. What would best practice look like for us to educate, but maintain social distance? I believe we can manage a lot of the operationalizing but would be immensely grateful for some high-level guidance to follow.

I recognize how incredibly busy this time is for you and would be so incredibly grateful for any time you might be willing to spare for this audience.

With immense gratitude,
Chris Joffe

CEO | Joffe Emergency Services
HQ | Santa Monica, CA
Twitter: @joffechris

Executive Assistant
E: (b) (6)
P: (b) (6)
Here it is

Begin forwarded message:

Sent: Tue, 7 Apr 2020 13:12:39 -0400
To: Lane, Cliff [NIH/NIAID] [E]
Subject: Fwd: [b][6]
Attachments: [b][4]
Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b)(6)  
FAX: (301) 496-4409  
E-mail: (b)(6)  
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender’s own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E]  
Sent: Tuesday, April 7, 2020 11:09 AM  
To: Fauci, Anthony (NIH/NIAID) [E]  
Subject: FW: NFLPA-NFL Task Force

Pls see below—

From: Billet, Courtney (NIH/NIAID) [E]  
Sent: Saturday, April 4, 2020 12:06 PM  
To: Conrad, Patricia (NIH/NIAID) [E]  
Cc: Folkers, Greg (NIH/NIAID) [E]; Auchincloss, Hugh (NIH/NIAID) [E]  
Subject: RE: NFLPA-NFL Task Force

From:  
Sent: Saturday, April 4, 2020 11:01 AM
Hi Courtney,

1st, I hope you, your family and your loved ones are harboring safely through this storm. 2nd, thanks for your efforts and those of Dr. Fauci—he is truly a national treasure during this crisis and it is deeply appreciated.

I appreciate your help and introductions on how our players can be helpful. As you know Drew and Brittany Brees made a $5M contribution to the Louisiana coronavirus efforts and they have done a lot of press. Drew’s message has been “Hang in there—hang tough! We are in this together.”

I’ve done several webinars with our players and their families, both educating them and pointing out their role both with friends and family as well as on social media to let NFL fans know that whether or not we have an NFL season depends to a large extent upon those fans following the guidelines zealously—as zealously as they follow NFL games!

That message seems to be getting through.

I write now with a request for a little bit of Dr. Fauci’s time in about 2 weeks. I requested that we stand up a joint NFLPA-NFL Task Force to scenario plan a pathway to getting NFL Club facilities open, with a view towards if and when we might look towards an NFL season, even if games are played with no fans. My request is to have Dr. Fauci give a telephone briefing to our group on this difficult topic, which would of course be confidential. The floor would be his and I can brief him prior to the call on what we have been working on. If he were willing, we can do the call anytime, probably during the week of April 13, although of course the modeling shows that would be during the peak of the outbreak. We could also do it the week before or after.

Thanks so much for considering this. We are mindful of the psychological toll the virus is taking and the lift NFL games would give to a sports-starved population, but only if it can be done safely for the players and the fans who (ultimately) allow them to play this great game.

Again, thanks!

Best,

Doc

Thom Mayer, MD, FACEP, FAAP, FACHE
Medical Director

NFLPA
NFL Players Association
11150 Sunset Hills Road, Ste 305
Reston, VA 20190
RE: BCG protection from COVID-19 mortality

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-4409
Fax: (301) 496-4409
E-mail: (b)(6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Good morning Tony,
All the best,

Carolina

--------------------------------------------------
Carolina Barillas Mury, M.D., Ph.D.
Chief, Mosquito Immunity and Vector Competence Section
Laboratory of Malaria and Vector Research
National Institutes of Health
12735 Twinbrook Parkway, Room 2E-20C
Rockville, MD 20852
Phone: (301) 480 0930  Fax: (301) 480 0930
E-mail: (b)(6)
From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 7 Apr 2020 14:51:59 +0000
To: Alison Galvani
Subject: RE: Your PNAS article "Projecting hospital utilization during the COVID-19 outbreaks in the United States" has published

Alison:

Thanks for sending this. I hope that all is well with you. Keep up your great work.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-4409
Fax: (301) 496-4409

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are not the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Alison Galvani
Sent: Friday, April 3, 2020 3:34 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Singer, Burton H (b) (6); Seyed Moghadas (b) (6)
Subject: Fwd: Your PNAS article "Projecting hospital utilization during the COVID-19 outbreaks in the United States" has published

Hi Tony,

Please find attached our second COVID publication. This one focuses on projections of the number of ICU beds that will be needed at the peak of the outbreak.

Please don't hesitate to let me know if we can be of any assistance.

Take care,
Alison
PNAS is pleased to announce that your paper "Projecting hospital utilization during the COVID-19 outbreaks in the United States" has published online at: www.pnas.org. Did you know article-level metrics data and article downloads are now available for all PNAS articles? Article-level metrics provide a new way of measuring the reach and impact of an article by tracking the mentions it receives online. Clicking on the "Authors & Info" tab near the top of each article and scrolling down will reveal a summary of mentions of the article across news sites, blogs, social media, and other online sources—which are visualized in a colorful icon, or "badge." The number in the middle of the badge is the Altmetric score, which is based on the volume, type, and author of the mentions. You can click on the badge or "view more" to explore the individual mentions from each source. Article downloads by month and by article format appear below the badge.

Stay connected to PNAS:

Follow Us on Twitter
Find Us on Facebook

---

Alison Galvani, PhD

Director, Yale Center for Infectious Disease Modeling and Analysis (CIDMA)
Burnett and Slender Families Professor of Epidemiology
Yale School of Public Health
Yale School of Medicine
New Haven, CT 06520

http://cidma.yale.edu/

Follow me at @Alison_Galvani
Follow CIDMA @YCIDMA
Thanks, Roger!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted]
FAX: (301) 496-4409
E-mail: [redacted]

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender’s own and not expressly made on behalf of the NIAID by one of its representatives.

Tony

Read the last lines and see the photo! Your words from the past are remembered and have changed the careers of our fellows.

No need to respond.

Roger

Sent from my iPad

Begin forwarded message:

From: [redacted]
Date: April 3, 2020 at 11:30:23 AM CDT
To: "Glass, Roger (NIH/FIC) [E]" [redacted]
Subject: Hello

Dr. Glass,
I hope you are well and I wanted to check in to see how you are doing in this scary and traumatic time for our world.

During these times, I'm especially thankful for the training I received from the Fogarty Institute. I remember your wise words at our Fogarty orientation in 2011- on why investing in Global health is so critical. No truer words have been spoken especially at times like these!

I'm currently communicating with my former colleagues in Zambia (Mpanji and Innocent pictured here with me [https://www.thermofisher.com/blog/behindthebench/using-sanger-sequencing-to-detect-drug-resistance-mutations-in-hiv-in-zambia/] from CIDRZ to see how testing can be brought up via the public health infrastructure in place currently. Thankfully, the number of cases is very low, although the unreported cases are much higher than likely captured ([https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9eef6]). My friend who is a Lieutenant Physician actually likely contracted COVID-19 in January and wrote that she and others had treated a patient returning from Wuhan who was pregnant of respiratory illness upon coming back to Lusaka to deliver, only to die of pleural effusion later. They subsequently developed flu-like symptoms and resolved, but these are the types of cases that likely go undetected and can potentially contribute to community spread of the disease.

Thank you again for being such a wonderful role model, and I look to leaders like you and Dr. Fauci to help our nation think with prudent but difficult decisions.

Kind regards,

Lillian
Why invest in global health?

- Good for science – the new frontier
- Good for diplomacy – “smart power”
- Good for humanity – correct health disparities
- Good for business & competition
- Good for our war on terrorism
- Good for our own future

Just the right thing to do!

Research to Develop and Optimize Interventions Against Infectious Disease Threats

Implementation: Delivery of Proven Interventions to Patients and Populations
What do you think of this study?

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-2263
FAX: (301) 496-4409
E-mail: afauci@niaid.nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Dear Tony and Michael:

Hang in there —
Jeff Gelfand
Mark Poznansky
Vaccine and Immunotherapy Center
Division of Infectious Diseases
Massachusetts General Hospital
Dear Jeff and Mark,

Thanks,
Huabiao

attached please find the supporting information in PDF

If needed please download the supporting information
Dear Jeff,

I had a chance getting this information from Dr. Danlei Mou who works very diligently and seriously on this clinical study. You may be interested in this primary information. Please keep it confidential.

Best, Huabiao

The information in this e-mail is intended only for the person to whom it is addressed. If you believe this e-mail was sent to you in error and the e-mail contains patient information, please contact the Partners Compliance HelpLine at http://www.partners.org/complianceline. If the e-mail was sent to you in error but does not contain patient information, please contact the sender and properly dispose of the e-mail.
Thanks, Fred. I appreciate your note.
Best regards,
Tony

-----Original Message-----
From: Upton, Fred
Sent: Saturday, April 11, 2020 6:31 PM
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Re: GOP lawmakers: Fauci may be doing more harm than good | TheHill

Update. Biggs and Buck are the only 2 members of Congress that voted agn the first two bills dealing with COVID-19. The first vote had only the 2 of them vote no. NR

Sent from my iPhone

> On Apr 11, 2020, at 5:45 PM, Upton, Fred wrote:
> It's upton again and no need to respond. U may get asked about this story and u should know that both Buck and Biggs were among the 40 that voted no on the 2nd package which provided assistance and testing (think it was $13B). It was not a surprise that they voted no as they r joined with Tom Massie in almost everything. Keep being a science truth teller
> 
> Sent from my iPhone
Fred:
Thanks for the note. The answer is almost certainly yes, but there would not be enough of them whereby we can compare the results in those who were receiving Hydroxychloroquine or not for their lupus. Large natural history studies, which we will be initiating could possibly answer that question.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b)(6)
FAX: (301) 496-4409
E-mail: (b)(6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Upton, Fred (b)(6)
Sent: Friday, April 10, 2020 6:01 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b)(6)
Subject: It's Fred upton

U gave me your email at the Capitol briefing. Question, with all the discussion on hydrox.—have there been any Covid-19 cases that have struck lupus victims? TY

Sent from my iPhone
Thanks, Ken. Interesting concept. I will run it by our program people.

Hi, Tony
This is not my field but I had some ideas, so thank you for indulging me in thinking about “why not kids.” I attached citations I found useful. Hope you are not sorry you asked... ☺️
Best regards,

Ken

From: Fauci, Anthony (NIH/NIAID) [E] (b)(6)
Sent: Tuesday, April 07, 2020 9:50 AM
To: Bergmann, Kenneth (b)(6)
Subject: RE: a thought on selective vulnerability to SARS-CoV-2

Ken:
  Thanks for the note. I have thought about the same or similar issues. (b)(5)

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b)(6)
FAX: (301) 496-4409
E-mail: (b)(6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.
Dear Dr. Fauci,

I read with interest your JAMA Viewpoint of February 25.

Thank you for all you do.

Sincerely,

Ken

Kenneth J. Bergmann, MD, FAAN
Senior Medical Officer
Division of Neurology I, Office of Neuroscience
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Building 22, Room 4143
10903 New Hampshire Avenue,
Silver Spring, MD 20993-0002
Office: (b) (6)
Mobile: (b) (6)
Email: (b) (6)
Please check this out with program people. Thanks.

Hi, Tony
This is not my field but I had some ideas, so thank you for indulging me in thinking about “why not kids.” I attached citations I found useful. Hope you are not sorry you asked... 😊
Best regards,

Ken

From: Fauci, Anthony (NIH/NIAID) [E]< (b) (6)>
Sent: Tuesday, April 07, 2020 9:50 AM
To: Bergmann, Kenneth < (b) (6)>
Subject: RE: a thought on selective vulnerability to SARS-CoV-2

Ken:

Thanks for the note. I have thought about the same or similar issues. 

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not
accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Bergmann, Kenneth
Sent: Saturday, April 4, 2020 9:39 AM
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: a thought on selective vulnerability to SARS-CoV-2

Dear Dr. Fauci
I read with interest your JAMA Viewpoint of February 25.

Thank you for all you do.
Sincerely
Ken

Kenneth J. Bergmann, MD, FAAN
Senior Medical Officer
Division of Neurology I, Office of Neuroscience
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Building 22, Room 4143
10903 New Hampshire Avenue,
Silver Spring, MD 20993-0002
Office: (6) (6)
Mobile: (6) (6)
Email: (6) (6)
Please take a look at this and figure out whether we should do something.

Tony, Bob and Debi,

Amy is working on a pathway to collect data from electronic medical records in selected areas of the country (addressing all of the appropriate privacy concerns). We’re looking for data elements to collect and wonder if your teams could give us some insight from a public health perspective. I am copying Amy to see if she has anything else to add. Perhaps you could assign someone to work with Amy.

Thanks

Steve
Thanks, Brian. I appreciate your note.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-4409
FAX: (301) 496-4409
E-mail: (b)(6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Tony,

Thank you for all that you are doing in the fight against COVID-19. Your steady leadership and grounding in the science, and your ability to communicate complex information clearly to policymakers and the public, are what the world needs during this crisis. I know we will see the other side of this pandemic, and you will have once again saved many lives with your work.

I am one step removed from this response, as I am on a detail assignment from FEMA to the Naval Academy, but have been sharing information with the Superintendent and his senior leadership team so that they can make good decisions to protect the community while meeting the Academy’s mission. I have thought back to the H1N1 response in 2009-2010 many times since this began.

Again, thank you for what you’re doing. My best wishes to you and your family.

Best,
Brian
From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 16 Apr 2020 03:00:26 +0000
To: Collins, Francis (NIH/OD) [E]; Myles, Renate (NIH/OD) [E]; Tabak, Lawrence (NIH/OD) [E]; Wolinetz, Carrie (NIH/OD) [E]; Lane, Cliff (NIH/NIAID) [E]
Cc: Burklow, John (NIH/OD) [E]; Fine, Amanda (NIH/OD) [E]; Wojtowicz, Emma (NIH/OD) [E]; Fritz, Craig (NIH/OD) [E]; Billet, Courtney (NIH/NIAID) [E]; Stover, Kathy (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]
Subject: RE: For review tonight: draft Sec. Azar statement on ACTIV

Ditto.

From: Collins, Francis (NIH/OD) [E]
Sent: Wednesday, April 15, 2020 10:57 PM
To: Myles, Renate (NIH/OD) [E]; Tabak, Lawrence (NIH/OD) [E]; Wolinetz, Carrie (NIH/OD) [E]; Lane, Cliff (NIH/NIAID) [E]; Fauci, Anthony (NIH/NIAID) [E]; Fine, Amanda (NIH/OD) [E]; Wojtowicz, Emma (NIH/OD) [E]; Fritz, Craig (NIH/OD) [E]; Billet, Courtney (NIH/NIAID) [E]; Stover, Kathy (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]
Cc: Burklow, John (NIH/OD) [E]; Fine, Amanda (NIH/OD) [E]; Fritz, Craig (NIH/OD) [E]; Billet, Courtney (NIH/NIAID) [E]; Stover, Kathy (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]
Subject: RE: For review tonight: draft Sec. Azar statement on ACTIV

Looks generally OK
FC

From: Myles, Renate (NIH/OD) [E]
Sent: Wednesday, April 15, 2020 10:44 PM
To: Collins, Francis (NIH/OD) [E]; Tabak, Lawrence (NIH/OD) [E]; Wolinetz, Carrie (NIH/OD) [E]; Lane, Cliff (NIH/NIAID) [E]; Fauci, Anthony (NIH/NIAID) [E]; Fine, Amanda (NIH/OD) [E]; Wojtowicz, Emma (NIH/OD) [E]; Fritz, Craig (NIH/OD) [E]; Billet, Courtney (NIH/NIAID) [E]; Stover, Kathy (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]
Cc: Burklow, John (NIH/OD) [E]; Fine, Amanda (NIH/OD) [E]; Fritz, Craig (NIH/OD) [E]; Billet, Courtney (NIH/NIAID) [E]; Stover, Kathy (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]
Subject: FW: For review tonight: draft Sec. Azar statement on ACTIV
Importance: High

Good evening:

I’m sending this directly to principals given the quick turnaround. I’ve let ASPA know that the goal is to issue the release sometime tomorrow.

Thanks,
Renate
From: Brennan, Patrick (OS/ASPA)  
Sent: Wednesday, April 15, 2020 10:20 PM  
To: Burklow, John (NIH/OD) [E]  
Fritz, Craig (NIH/OD) [E]  
Myles, Renate (NIH/OD) [E]  
Fine, Amanda (NIH/OD) [E]  
Wojtowicz, Emma (NIH/OD) [E]  
Akinso, Woleola (NIH/OD) [E]  
Stimson, Brian (HHS/OGC)  
Charrow, Robert (HHS/OGC)  
Murphy, Ryan (OS/ASPA)  
Pratt, Michael (OS/ASPA)  
Oakley, Caitlin B. (OS/ASPA)  
Cc:  
Subject: For review tonight: draft Sec. Azar statement on ACTIV

NIH and OGC,

Can you let me know if the below and attached statement from the Secretary looks OK? **Assuming it is going tonight from NIH, approval as soon as possible would be great.** Thank you!

- Patrick

Patrick Brennan
Director of Speechwriting
Department of Health and Human Services
Office:  
Cell:
I want to share with you the product of the BCG team who drafted the attached briefing and Decision Memo drafted for the Secretary’s review tomorrow. I want to thank all those who contributed over this holiday weekend to offer their ideas and concepts that is represented in these products. This represents just a first step of many steps that first outlines a concept that will then be operationalized into a historic effort for not only the Department and agencies who will contribute to it, but to our Nation. Again, thank you for your contributions and commitment. Best Bob
This looks really good. Thanks.

Per request from the Secretary's office that I sent you this morning, below is what I propose to submit tomorrow morning for the new daily 9am data call. I will plan to submit pretty much the same thing every day. I will not clog your in-box with it unless there is a significant update.

RFI from Staff Sec:

1. For tomorrow's press conference, what information or topics do you recommend be included in the President's remarks? Please provide talking point-level details and support.

Nothing specific from NIAID at this time.

2. For tomorrow's press conference, on what information (if any) do you intend to speak?

Specific topics will depend on questions from reporters. Dr. Fauci has been asked about the effect of social distancing; considerations that would factor into returning the country to normal life; off-label use of treatments such as hydroxychloroquine; the status of clinical trials; and the disproportionate impact of COVID-19 on communities of color.

NIAID-specific talking points:

- NIAID has mobilized a rapid research response to quickly develop effective countermeasures for COVID-19, including diagnostics, vaccines to prevent disease and treatments.
• NIAID is supporting a clinical trial of the antiviral remdesivir and is investigating other treatments, including antibody therapies and other antivirals, for their activity against SARS-CoV-2. Well-designed clinical trials are the best way to evaluate potential treatments for safety and efficacy.

• NIAID is supporting an early-stage clinical trial of an investigational vaccine called mRNA-1273, developed by NIAID scientists and the biotechnology company Moderna. The study launched first in Seattle, with a second site recently added in Atlanta. NIAID is researching additional vaccine candidates.

• NIAID has launched a serosurvey study that aims to determine how many adults in the United States without a confirmed history of COVID-19 have antibodies to the virus. Researchers will collect and analyze blood samples from as many as 10,000 adult volunteers without a confirmed history of COVID-19. The results will help illuminate the extent to which the novel coronavirus has spread undetected in the United States and provide insights into which communities and populations are most affected. [NOTE: This serosurvey is for research purposes. It is not meant to be a way for people to access antibody testing for personal knowledge of prior infection history. If it is portrayed as a way for people to “get tested” to understand their own infection history, we can expect that people will inaccurately blame the government for not receiving results in a timely manner. People can request to learn about their results, which will be available only after weeks or months of analysis.]

• NIAID is expanding its portfolio of basic research on coronaviruses and emerging pathogens to characterize SARS-CoV-2 (the virus that causes COVID-19) and understand how it causes disease. NIAID also is using animal models to better understand the infection and to investigate optimal ways to treat and prevent COVID-19.

3. Are there topics or announcements for future press conferences (other than tomorrow’s) that you would like to flag for the President’s speechwriting team?

For HHS to consider mentioning: ____________________________

From: Fauci, Anthony (NIH/NIAID) [E] ____________________________
Sent: Sunday, April 12, 2020 1:55 PM
To: Billet, Courtney (NIH/NIAID) [E] ____________________________
Subject: RE: Staff Sec POC - NIAID ____________________________
OK. Sounds fine. Do what you can do.

FYI – per request below, HHS is setting up a daily data call. We need to tell them at 9am what you are going to discuss at the daily press conference at the end of the day. My observation is that this may be hard to predict. However, we can certainly come up with some boilerplate talking points that we re-submit every day, emphasizing the importance of properly designed clinical trials as the best way to identify treatments.

Hi Courtney -

I hope you’re having a good weekend. Just wanted to touch base because starting tomorrow, we will be receiving requests for information from Staff Sec each evening ahead of the next day’s press conference - for a turnaround by 9am the following morning. Staff Sec is requesting feedback (see the questions below) from task force experts, including Dr. Fauci, on information they recommend be included in the next day’s press conference.

Could you please help me identify a primary POC at NIAID that I can work with to get information to Staff Sec?
Thank you.
Natalie

Natalie Boyse
Special Assistant, Immediate Office of the Secretary
U.S. Department of Health & Human Services

M: [Redacted]
I am sorry, but I am way behind on e-mails and I just saw this. What is going on here?

Just saw this. Huh? 

From: Kadlec, Robert (OS/ASPR/O) [E] (b) (6)
Sent: Friday, April 10, 2020 7:27 PM
To: Hassell, David (Chris) (OS/ASPR/O) (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Collins, Francis (NIH/OD) [E] (b) (6); Dareshori, Zack (HHS/IOS) (b) (6); Disbrow, Gary (OS/ASPR/BARDA) (b) (6); Moughalian, Jen (HHS/ASFR) (b) (6); Shuy, Bryan (OS/ASPR/O) (b) (6); Redfield, Robert R. (CDC/OD) (b) (6); strength-McGaughey, Tracie (CDC/DDID/NCIPC/OD) (b) (6); Marks, Peter (FDA/CBER) (b) (6); Cochran, Norris (HHS/ASFR) (b) (6); Messonnier, Nancy (CDC/DDID/NCIRD/OD) (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6); Johnson, Robert (OS/ASPR/BARDA) (b) (6); Gershman, Lynn E. (CDC/DDPHSIS/OD) (b) (6); Lenihan, Keagan (FDA/OC) (b) (6); Mascola, John (NIH/VRC) [E] (b) (6)
First thank you all for participating on Wednesday’s evening call and producing the briefing memo for the Secretary’s review. As a consequence of that meeting and discussion, he fully endorsed the recommendations of the vaccine portfolio you recommended. He, however, expressed concern about

This is an ambitious and challenging undertaking but one driven by the necessity to mitigate the public health, economic and national security threat this virus represents to our citizens, nation and our way of life. The Secretary is confident that together with our private sector partners this is achievable.

Have a restful holiday weekend.

Bob

From: Hassell, David (Chris) (OS/ASPR/IO) (b)(6)
Sent: Thursday, April 9, 2020 3:13 PM
To: Kadlec, Robert (OS/ASPR/IO) (b)(6); Conrad, Patricia (NIH/NIAID) (b)(6); Collins, Francis (NIH/OD) (b)(6);
Subject: COVID-19 Advisory Panel Recommendations

Dear Panel members —

Secretary Azar requested a summary paper with a recommendation from the Panel re the BARDA vaccine portfolio. His deadline was 3:30pm today.

Based on the discussion last night and other discussions with the BARDA team, Please let me know as soon as possible if this is not the case.

Apologies for the fast turn. Thank you again for your participation in the Panel.

Chris

<< File: COVID Vaccines Briefing Memo V.3.docx >>
To: Kadlec, Robert (OS/ASPR/IO); Conrad, Patricia (NIH/NIAID) [E]; Collins, Francis (NIH/OD) [E]; Dareshori, Zack (HHS/IOS); Bright, Rick (OS/ASPR/BARDA); Disbrow, Gary (OS/ASPR/BARDA); Ford-Barnes, Arwenthia (OS/ASPR/IO); Blatner, Greta (OS/ASPR/BARDA); Patrick, Vanessa (OS/ASPR/BARDA) (CTR); Moughalian, Jen (HHS/ASFR); Shuy, Bryan (OS/ASPR/IO); Redd, John (OS/ASPR/SPPR); Tignor, Beth (HHS/IOS); Redfield, Robert R. (CDC/OD); Strength-McGaughy, Tracie (CDC/DDNID/NCIPC/OD); Hassell, David (Chris) (OS/ASPR/IO); Yeskey, Kevin (OS/ASPR/IO); Callahan, Victoria (OS/ASPR/IO) (CTR); Moreno, Rafael (OS/ASPR); Marks, Peter (FDA/CBER); Cochran, Norris (HHS/ASFR); Messonnier, Nancy (CDC/DDID/NCIRD/OD); Windom, Robert (OS/ASPR/IO); Lane, Cliff (NIH/NIAID) [E]; Holland, Tara (OS/ASPR/EMMO); Johnson, Robert (OS/ASPR/BARDA); Gershman, Lynn E. (CDC/DDPHSIS/OD); Kemp, Micha (OS/ASPR/MFHC); Lenihan, Keagan (FDA/OC); Mark Hartell [E]; Mascola, John (NIH/VRC) [E]; Suhana, Tina (NIH/VRC) [E]; Marston, Hilary (NIH/NIAID) [E]; Fauci, Anthony (NIH/NIAID) [E]

Subject: #2 - COVID-19 Advisory Panel

When: Wednesday, April 8, 2020 5:15 PM-6:30 PM (UTC-05:00) Eastern Time (US & Canada).

Where: WEBEx -

Presentation for Wednesday. THIS IS THE UPDATED VERSION 4:26pm

<< File: BARDA COVID Vaccines White Paper 20200405b.docx >>

Meeting Objective:

(1) Complete review of BARDA vaccine portfolio (to include related NIH and DoD programs), with emphasis on discussion among Panel members;

(2) Formulate a recommendation to Secretary Azar to either endorse or modify current vaccine strategy, plans, proposed funding and contracts.

Agenda

Brief review of vaccine programs

- BARDA (deeper dive after Sunday overview)
- NIAID
- DoD

Discussion

Recommendation to Secretary Azar

For convenience, below are the presentation and White Paper from last Sunday evening.

<< File: BARDA COVID Portfolio Review 20200405b.pptx >> << File: Vaccine Discussion with S1 and HHS Leadership V2 FINAL - Gary.pdf >>

Hi Arwenthia Ford-Barnes,

You updated this WebEx meeting:

#2 COVID-19 Advisory Panel on behalf of Dr. Robert Kadlec
Host: Arwenthia Ford-Barnes

When it's time, start your meeting from here:

**Start the meeting**

When: Wednesday, April 8, 2020, 5:15 pm (1 hr 15 mins), Eastern Daylight Time (New York, GMT-04:00).

Access Information

Meeting Number:

Password:

(This meeting does not require a password.)

Host Key:

(Use this key during the meeting if you ever need to reclaim the host role.)

Audio Connection

(Meeting Server Main Number)

Access Code:

Delivering the power of collaboration

The meetingserver.hhs.gov team

© 2020 Cisco and/or its affiliates. All rights reserved.

How do we nicely say no to this person?

Begin forwarded message:

From: "Sachdev, Amit (HHS/IOS)" [b][a]
Date: April 9, 2020 at 2:04:56 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" [b][a]
Subject: Hello

Hi Dr. Fauci, my name is Amit Sachdev. I am a White House fellow and physician most recently at the Brigham.

I know you are super busy and I would love to partner with you and write an op ed on coronavirus and unite the nation.

If you have a few minutes, I would love to speak. I think

Thank you for your time and consideration.

Sincerely,
Amit

Sent from my iPhone
Please text to me your cell phone number

On Apr 8, 2020, at 7:29 PM, Adams, Jerome (HHS/OASH)

Also, Deb has the data and knows it better than anyone;

VADM Jerome Adams
20th US Surgeon General

On Apr 8, 2020, at 7:13 PM, Adams, Jerome (HHS/OASH)

With greatest of respect to the two of you,
VADM Jerome Adams
20th US Surgeon General
FYI

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender’s own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stecker, Judy (OS/IOS) (b) (6)
Sent: Wednesday, April 8, 2020 9:59 AM
To: Harrison, Brian (HHS/IOS) (b) (6)
Cc: (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6)
Subject: Re: HHS Sponsored Coronavirus Clinical Guidelines - Heads up

Thank you. Will have Beth connect with Patricia ASAP.

Sent from my iPhone

On Apr 8, 2020, at 9:48 AM, Harrison, Brian (HHS/IOS) (b) (6) wrote:

Sounds good, Dr. Fauci - we greatly appreciate the effort that you/Cliff and your team have put into this.

Look forward to receiving and discussing the guidelines (no need for a separate meeting with me first - we can go straight to the Secretary) and agree that they will not be subjected to additional layers of formal clearance given the circumstances.
Adding Judy to quickly help coordinate a time to meet with the Secretary.

Thanks again,

BH

Brian Harrison
Chief of Staff
U.S. Department of Health and Human Services

On Apr 8, 2020, at 7:46 AM, (B)(6) (OS/IOS) (b)(6) wrote:

Thank you Tony. Obviously we will prioritize time to meet/discuss. I'm at your disposal.

AMA

On Apr 7, 2020, at 11:01 PM, Fauci, Anthony (NIH/NIAID) [E] (b)(6) wrote:

Brian:
discuss further before I brief the Secretary.

Best regards,

Tony
Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted]
FAX: (301) 495-4409
E-mail: [redacted]

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender’s own and not expressly made on behalf of the NIAID by one of its representatives.
Thanks, Brian.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive. MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Sounds good, Dr. Fauci - we greatly appreciate the effort that you/Cliff and your team have put into this.

Look forward to receiving and discussing the guidelines (no need for a separate meeting with me first - we can go straight to the Secretary) and agree that they will not be subjected to additional layers of formal clearance given the circumstances.

Adding Judy to quickly help coordinate a time to meet with the Secretary.

Thanks again,

BH

Brian Harrison
Chief of Staff
U.S. Department of Health and Human Services
On Apr 8, 2020, at 7:46 AM, [REDACTED] (OS/IOS) wrote:

Thank you Tony. Obviously we will prioritize time to meet/discuss. I'm at your disposal.
AMA

On Apr 7, 2020, at 11:01 PM, Fauci, Anthony (NIH/NIAID) [E] wrote:

Brian:

[REDACTED]. Happy to discuss further before I brief the Secretary.
Best regards,
Tony
Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b)(6)
FAX: (301) 496-4409
E-mail: (b)(6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.
Karen:

Thanks for your note.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

Hi, Dr. Fauci.

Thank you so much for keeping things honest and know that I am such a champion of you.

I hope that reaching out is okay. I work at HHS/IOS team. As I sit here at home and have been thinking about the shortage of medical supplies, doggie cones actually can be used as protection for our health care workers. Just a thought that looks and sounds crazy but can help.

Stay safe.
Kindest Regards,

Karen Becks
U.S. Department of Health and Human Services
Immediate Office of the Secretary
200 Independence Avenue, SW
Washington, DC 20201
Desk: (b)(6)
Mobile: (b)(6)